Atossa Genetics Inc (NASDAQ:ATOS) shares surged nearly 19 percent in the current trading session after the development-stage healthcare company said that its board has given consent for the adoption of a stockholder rights agreement. Company stock is trading in the range of $1.22 to $1.54. The company has a market capitalization of $35.67 million. Atossa Genetics Inc (NASDAQ:ATOS) weekly performance is 59.17%. On last trading day company shares ended up $1.91. Analysts mean target price for the company is $8.75. Atossa Genetics Inc (NASDAQ:ATOS) distance from 50-day simple moving average (SMA50) is 29.47%.
St. Paul-based med-tech company MGC Diagnostics Corporation (NASDAQ:MGCD) announced that CEO Gregg Lehman is leaving the firm to become CEO of a healthcare and wellness program provider. MGC Diagnostics Corp (NASDAQ:MGCD) shares fell -0.30% in last trading session and ended the day on $89.82. MGCD Gross Margin is 56.30% and its return on assets is 6.70%. MGC Diagnostics Corp (NASDAQ:MGCD) quarterly performance is -14.39%.
QLT Inc. (USA) (NASDAQ:QLTI) saw a big move last session, as the company’s shares fell by over 9% on 14 May 2014. The move came on pretty good volume too with far more shares changing hands than in a normal session. This continues the most recent downtrend for the company as the stock is now down nearly 22% since April 24. QLT Inc. (USA) (NASDAQ:QLTI) shares moved up 8.33% in last trading session and was closed at $5.33, while trading in range of $4.90 – $5.53. QLT Inc. (USA) (NASDAQ:QLTI) year to date (YTD) performance is -4.31%.
Lumenis Ltd (NASDAQ:LMNS) released its earnings data on Wednesday. The company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.02. Analysts at Zacks initiated coverage on shares of the company in a research note on Wednesday, April 16th. They set a “hold” rating on the stock. On the ratings front, analysts at Wells Fargo & Co. reiterated a “buy” rating on shares of company in a research note on Monday, April 14th. Lumenis Ltd (NASDAQ:LMNS) ended the last trading day at $8.77. Company weekly volatility is calculated as 4.45% and price to cash ratio as 7.38. Lumenis Ltd (NASDAQ:LMNS) showed a negative weekly performance of -4.05%.
Provectus Pharmaceuticals Inc (NYSEMKT:PVCT) tumbled -17.04%, the company’s corporate website of Provectus Biopharmaceuticals now describes PV-10 as an “investigational” drug for cancer, which is a change from the site’s description as of yesterday, which called PV-10 a “breakthrough” drug, reported TheStreet’s Adam Feuerstein, who noted that the company is supposed to hear back this week about its request for the FDA to grant the drug Breakthrough status as a skin cancer treatment. Provectus Pharmaceuticals Inc (NYSEMKT:PVCT) weekly performance is -14.04%. On last trading day company shares ended up $2.02. Analysts mean target price for the company is $3.50. Provectus Pharmaceuticals Inc (NYSEMKT:PVCT) distance from 50-day simple moving average (SMA50) is -15.81%.
Leave a Reply